What one share of Tyra Biosciences holds
We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology.
Tyra Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.40 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.78 |
| Cash and investments | $1.24 |
| Book value | $5.93 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$6.05 | $0.20 | −$5.24 | — | −$7.46 |
| 2021 | — | −$1.91 | $0.05 | −$1.77 | — | — |
| 2022 | — | −$1.32 | $0.01 | −$1.21 | — | $6.09 |
| 2023 | — | −$1.62 | $0.02 | −$1.19 | — | $4.75 |
| 2024 | — | −$1.51 | $0.01 | −$1.23 | — | $6.76 |
| 2025 | — | −$2.01 | $0.00 | −$1.60 | — | $4.83 |
Common questions about Tyra Biosciences
How much does one share of Tyra Biosciences earn?
Over the last 12 months, Tyra Biosciences lost $2.40 for each share.
Does Tyra Biosciences pay a dividend?
Tyra Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Tyra Biosciences’s book value per share?
Tyra Biosciences’s book value is $5.93 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Tyra Biosciences have?
Each share of Tyra Biosciences has $1.24 of cash and investments, as of June 30, 2026.
What is Tyra Biosciences’s free cash flow per share?
−$1.78 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Tyra Biosciences bought back shares?
Tyra Biosciences’s share count rose about 3765% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.